JP2022520978A5 - - Google Patents
Info
- Publication number
- JP2022520978A5 JP2022520978A5 JP2021548221A JP2021548221A JP2022520978A5 JP 2022520978 A5 JP2022520978 A5 JP 2022520978A5 JP 2021548221 A JP2021548221 A JP 2021548221A JP 2021548221 A JP2021548221 A JP 2021548221A JP 2022520978 A5 JP2022520978 A5 JP 2022520978A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- amino acid
- polypeptide according
- domain
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962807190P | 2019-02-18 | 2019-02-18 | |
| US62/807,190 | 2019-02-18 | ||
| PCT/US2020/018680 WO2020172189A1 (en) | 2019-02-18 | 2020-02-18 | BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520978A JP2022520978A (ja) | 2022-04-04 |
| JP2022520978A5 true JP2022520978A5 (cg-RX-API-DMAC10.html) | 2023-02-09 |
Family
ID=72144178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548221A Pending JP2022520978A (ja) | 2019-02-18 | 2020-02-18 | オルソポックスウイルス主要組織適合性複合体(mhc)クラスi様タンパク質(omcp)と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質 |
Country Status (11)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| JP2021523140A (ja) * | 2018-05-07 | 2021-09-02 | ドラゴンフライ セラピューティクス, インコーポレイテッド | Nkg2d、cd16、及び腫瘍関連抗原に結合するタンパク質 |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| JP2024529381A (ja) * | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1266014A2 (en) * | 2000-03-24 | 2002-12-18 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| US20110123440A1 (en) * | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| US20120294857A1 (en) * | 2010-01-11 | 2012-11-22 | Trustees Of Dartmouth College | Monomeric Bi-Specific Fusion Protein |
| LT3227311T (lt) * | 2014-12-05 | 2022-02-25 | Xyphos Biosciences Inc. | Įterpiami variabilūs antikūnų fragmentai ir nkg2d ligandų modifikuoti a1-a2 domenai |
| WO2016100375A2 (en) * | 2014-12-15 | 2016-06-23 | Washington University | Compositions and methods for targeted cytokine delivery |
| CN107530424A (zh) * | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| FR3035879B1 (fr) * | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
| HUE067376T2 (hu) * | 2015-08-04 | 2024-10-28 | Xyphos Biosciences Inc | Antitestek beilleszthetõ változó fragmentumai és NKG2D ligandumok módosított a1-a2 doménjei, valamint nem természetes NKG2D receptorokat megkötõ nem természetes NKG2D ligandumok |
| CN106467576B (zh) * | 2015-08-18 | 2020-04-07 | 中国科学院微生物研究所 | 一种抗体融合蛋白及其制备方法与应用 |
| US11053293B2 (en) * | 2016-02-05 | 2021-07-06 | Washington University | Compositions and methods for targeted cytokine delivery |
| AU2017222700B2 (en) * | 2016-02-26 | 2018-09-27 | Imunexus Therapeutics Limited | Multi-specific molecules |
| EP3475300A2 (en) * | 2016-06-24 | 2019-05-01 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands |
| CN110944651A (zh) * | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| CN107226866A (zh) * | 2017-07-05 | 2017-10-03 | 中国药科大学 | 一种抗cd24人源化抗体融合蛋白 |
-
2020
- 2020-02-18 US US17/431,664 patent/US20230002450A1/en not_active Abandoned
- 2020-02-18 AU AU2020226493A patent/AU2020226493B2/en active Active
- 2020-02-18 GB GB2112934.1A patent/GB2596001B/en active Active
- 2020-02-18 WO PCT/US2020/018680 patent/WO2020172189A1/en not_active Ceased
- 2020-02-18 KR KR1020217029846A patent/KR20210131373A/ko not_active Ceased
- 2020-02-18 CN CN202080029631.XA patent/CN114072416A/zh active Pending
- 2020-02-18 JP JP2021548221A patent/JP2022520978A/ja active Pending
- 2020-02-18 EP EP20759058.9A patent/EP3927722A4/en active Pending
- 2020-02-18 SG SG11202108878VA patent/SG11202108878VA/en unknown
- 2020-02-18 CA CA3130582A patent/CA3130582A1/en active Pending
-
2021
- 2021-08-17 IL IL285668A patent/IL285668A/en unknown
-
2025
- 2025-02-03 US US19/044,533 patent/US20260008822A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2596001A (en) | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class 1-like protein (OMCP) and tumor-specific binding partner | |
| JP2024099850A5 (cg-RX-API-DMAC10.html) | ||
| Yan et al. | Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment | |
| JP2024505887A5 (cg-RX-API-DMAC10.html) | ||
| JP7457899B2 (ja) | 修飾された免疫細胞及びその使用 | |
| Rizeq et al. | Towards understanding the mechanisms of actions of carcinoembryonic antigen‐related cell adhesion molecule 6 in cancer progression | |
| WO2023020423A1 (en) | Ror1 car or ror1 /cd19 dual car t cells for the treatment of tumors | |
| JP2021525731A5 (cg-RX-API-DMAC10.html) | ||
| JP2022514420A5 (cg-RX-API-DMAC10.html) | ||
| JP2021530243A5 (cg-RX-API-DMAC10.html) | ||
| JP2019531728A5 (cg-RX-API-DMAC10.html) | ||
| JP2021512614A5 (cg-RX-API-DMAC10.html) | ||
| JP2020522474A5 (cg-RX-API-DMAC10.html) | ||
| JP2019522054A5 (cg-RX-API-DMAC10.html) | ||
| JP2020521448A5 (cg-RX-API-DMAC10.html) | ||
| JP2025124799A (ja) | 細胞内部移行をモジュレートするための組成物および方法 | |
| JP2016531583A5 (cg-RX-API-DMAC10.html) | ||
| JP2022521183A5 (cg-RX-API-DMAC10.html) | ||
| Peng et al. | The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA | |
| CN102633883A (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| Haist et al. | Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas | |
| Chu et al. | Versatile CAR T-cells for cancer immunotherapy | |
| dos Santos et al. | Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| CN114650842A (zh) | 抗tim-3抗体 |